As 2025 draws to a close, the world faces new challenges from SARS-CoV-2 with the emergence of two subvariants: XFB, called “Stratus,” and NB.1.8.1, known as “Nimbus.” Although “the world has largely transitioned into a post-emergency phase,” these strains are bypassing existing immunity and driving new infections in the UK and the US.

Epidemiological data show a rise in viral activity since autumn as indoor gatherings increased. In Britain, “test positivity rates have surged past 8 percent,” according to the UK Health Security Agency. In the United States, wastewater surveillance reveals moderate to high viral levels in nearly all regions, with some states hitting “very high” markers. Hospital admissions haven’t reached early-pandemic peaks, but bed occupancy is straining healthcare workers who are also managing seasonal flu and RSV.

The clinical profile of these variants is distinct. Patients report symptoms differing from early COVID-19, notably the classic “loss of taste and smell.” Nimbus infections are marked by severe throat pain, described by many as “swallowing razor blades,” often with hoarseness or a “croaky” voice lasting several days. Other common symptoms include fatigue, congestion, and intense headaches.

Public health experts warn that this wave demonstrates how the virus continues to evolve, challenging both immunity and healthcare systems. Awareness of these new symptoms is key for early detection and care.

The winter season of 2025–2026 highlights that while vaccines and prior infections offer protection, the virus’s adaptability requires vigilance, particularly for the elderly and those with underlying health conditions.